Oogonial stem cell (OSC)-derived compositions, such as nuclear free cytoplasm or isolated mitochondria, and uses of OSC-derived compositions in autologous fertility-enhancing procedures are described.

Methods are provided of generating functional human oocytes following nuclear transfer of first polar body (PB1) genomes from metaphase II (MII) oocytes into enucleated donor MII cytoplasm (PBNT) and using mitochondrial replacement techniques to circumvent mother-to-child mtDNA disease transmission.

The present disclosure relates to methods for increasing telomere length in one or more human cells and/or increasing genome stability of one or more human cells, for example by contacting one or more human cells with an agent that increases expression of Zscan4 in the one or more human cells. Methods of treating a subject in need of telomere lengthening, treating a disease or condition associated with a genomic and/or chromosome abnormality, of rejuvenating one or more human cells, of rejuvenating tissues or organs, and of rejuvenating a subject in need thereof, for example by contacting one or more human cells in the subject with an agent that increases expression of Zscan4, or by administering to a subject in need thereof, an agent that increases expression of Zscan4 are also provided.

The present disclosure relates to methods for increasing telomere length in one or more human cells and/or increasing genome stability of one or more human cells, for example by contacting one or more human cells with an agent that increases expression of Zscan4 in the one or more human cells. Methods of treating a subject in need of telomere lengthening, treating a disease or condition associated with a genomic and/or chromosome abnormality, of rejuvenating one or more human cells, of rejuvenating tissues or organs, and of rejuvenating a subject in need thereof, for example by contacting one or more human cells in the subject with an agent that increases expression of Zscan4, or by administering to a subject in need thereof, an agent that increases expression of Zscan4 are also provided.

The present invention relates to improved assisted reproductive technology using highly purified menotropin (HP-hMG) to stimulate follicle development in controlled ovarian stimulation, particularly in women at risk of a high ovarian response to controlled ovarian stimulation.

Embodiments of the present invention provide plant-derived extracts as a replacement for traditional cryoprotectants used to freeze tissue and cell s providing a method to decrease post-thaw damage as created by the cryoprotectant. For example, extracts from the genus Hippophae or other plant sources or compositions may be used as a cryoprotectant or may even be used to replace at least some of a traditional cryoprotectant.

An apparatus and method for inducing human oocyte maturation in vitro, the apparatus including: a computing device, wherein the computing device includes at least a processor; and a memory communicatively connected to the at least processor, the memory containing instructions configuring the at least processor to receive first biological sample data from a first biological sample relating to a user; assign the user to a stimulation protocol as a function of the first biological sample; receive second biological sample data from a second biological sample relating to the user wherein the second biological sample comprises at least an immature oocyte; receive culture data relating the second biological sample; and assign the second biological sample a scoring metric as a function of the culture data of the second biological sample.

A method for improving the effect of the oocyte cryopreservation by reducing the mitochondrial temperature is provided. The invention uses a culture medium containing metformin for pretreatment before oocyte freezing; the pre-treated oocytes are then placed in a 20% ethylene glycol solution for balancing, and then the oocytes are placed in a vitrification solution for freezing and are submerged into liquid nitrogen. The method of this invention can effectively reduce the mitochondrial temperature of porcine oocytes, reduce the fluidity of cell membrane, and does not affect the embryonic development after parthenogenetic activation, it can restore the mitochondrial temperature of oocytes after thawing, improve the survival rate after thawing, which can effectively improve the utilization rate of frozen oocytes, it has wide application prospect.

The present invention provides modified oocytes having a nuclear genome derived from a first oocyte and cytoplasm derived from a second oocyte from a different subject, and methods for making and using such modified oocytes. The methods and compositions of the present invention can be useful in a variety of settings including, but not limited to, in in vitro fertilization (IVF) procedures.

The present disclosure relates to methods for increasing telomere length in one or more human cells and/or increasing genome stability of one or more human cells, for example by contacting one or more human cells with an agent that increases expression of Zscan4 in the one or more human cells. Methods of treating a subject in need of telomere lengthening, treating a disease or condition associated with a genomic and/or chromosome abnormality, of rejuvenating one or more human cells, of rejuvenating tissues or organs, and of rejuvenating a subject in need thereof, for example by contacting one or more human cells in the subject with an agent that increases expression of Zscan4, or by administering to a subject in need thereof, an agent that increases expression of Zscan4 are also provided.